Law Seminars International (LSI) will be offering a one-hour telebriefing on "The Myriad Decision: Practical Implications for Biotechnology Companies Protecting IP Assets" on July 17, 2013 from 3:00 to 4:00 pm (Eastern). Dr. Barbara R. Rudolph of Finnegan Henderson Farabow Garrett & Dunner LLP will moderate a panel that includes Jennifer L. Swize of Jones Day and Courtenay C. Brinckerhoff of Foley & Lardner LLP. The panel will discuss the Myriad decision and the possible implications for patent procurement, patent litigation, the biotechnology industry, and the future of medical research. Among the topics to be covered are:
Impact of the Myriad Decision on
patents for genetic research
• How the decision distinguishes between natural and synthetic gene sequences
• Legal and business implications for the biotech industry
• New strategies for protecting DNA-based intellectual property moving forward
A Q&A will follow the presentation and last for up to 30 minutes.
The registration fee is $150 per caller and $100 for each additional person on the same line who desires continuing education credit. Those interested in registering for the telebriefing, can do so here.